

AVITA THERAPEUTICS, INC. (ASX:AVH)

Exercise of unquoted options

Valencia, Calif., USA, and Melbourne, Australia, 5 August 2020: AVITA Therapeutics, Inc. (**Company**) advises that it has issued a total of 582 fully paid shares of common stock in the Company (**New Securities**) as a result of the cashless exercise of 86,242 warrants in the form of unquoted options in AVITA Medical Limited (**Avita Australia**) (which entitled the holder to be issued shares of common stock in the Company rather than ordinary shares in Avita Australia on a consolidation ratio of 100:1 as set out in the Company's pre-quotations disclosure released to the market on 24 June 2020).

The New Securities have not yet been registered under the U.S. Securities Act of 1933, as amended, or the securities laws of any state of the United States or in any other jurisdiction. The New Securities may not be offered, sold or transferred in the absence of an effective registration statement for the New Securities under applicable U.S. securities laws unless offered, sold or transferred pursuant to an available exemption from the registration requirements of those laws.

The New Securities will be subject to resale restrictions in the United States for a period of the earlier of six months from their date of issue or until the Company files its Form S-8 Registration Statement in relation to the New Securities with the U.S. Securities and Exchange Commission. The New Securities will be quoted on NASDAQ.

Authorised for release by the Chief Financial Officer of the Company.

###

ABOUT THE AVITA GROUP

The AVITA group is a regenerative medicine group of companies with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. The AVITA group's patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient's own skin. The medical devices work by preparing a RES[®] REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient's skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

The AVITA group's first U.S. product, the RECELL[®] System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin[™] Cells using a small amount of a patient's own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL[®] Autologous Cell Harvesting Device (<https://recellsystem.com/>) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.

To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This announcement includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this announcement include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this announcement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control such as any effects to the Company from the ongoing global COVID-19 pandemic. Investors should not place considerable reliance on the forward-looking statements contained in this announcement. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this announcement speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

FOR FURTHER INFORMATION:

<p>U.S. Media</p> <p>Sam Brown, Inc.</p> <p>Christy Curran</p> <p>Phone +1 615 414 8668</p> <p>christycurran@sambrown.com</p> <p>O.U.S Media</p> <p>Monsoon Communications</p> <p>Rudi Michelson</p> <p>Phone +61 (0)3 9620 3333</p> <p>Mobile +61 (0)411 402 737</p> <p>rudim@monsoon.com.au</p>	<p>Investors:</p> <p>Westwicke Partners</p> <p>Caroline Corner</p> <p>Phone +1 415 202 5678</p> <p>caroline.corner@westwicke.com</p> <p>AVITA Therapeutics, Inc.</p> <p>David McIntyre</p> <p>Chief Financial Officer</p> <p>Phone +1 661 367 9178</p> <p>dmcintyre@avitamedical.com</p>
--	---

PR08052020